Nature

Recognition of the nonclassical MHC class I molecule H2-M3 by the receptor Ly49A regulates the licensing and activation of NK cells

Natural killer (NK) cells contribute to immune responses to cancer 1,2 and viruses 3. Unlike the receptors on lymphocytes of the adaptive immune system, such as B cells and T cells, the receptor ...
Nature

On guard—activating NK cell receptors

Figure 2: The NKG2D-DAP10 receptor complex and its ligands. Remarkably, these additional human NKG2D ligands were initially identified by their ability to bind to the human cytomegalovirus-encoded ...
GEN

First-In-Class Immune Checkpoint Therapy Unlocks NK Cell Attack on Tumors

Scientists at Albert Einstein College of Medicine have developed a new anticancer strategy that they suggest could bolster the effectiveness of immune-checkpoint therapy. The team said their findings ...
Seeking Alpha

Coeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-in-Class Allogeneic NK Cell Therapy for the Treatment of Viral Infections

Novel NK cell therapy approach is designed to bolster and replenish the immune system during severe viral infection, which can severely reduce immune cells leading to hospitalization and death WEXFORD ...
EurekAlert!

MD Anderson and KKR-backed Replay form new product company Syena to pioneer first-in-class TCR NK cell therapy

HOUSTON, SAN DIEGO and LONDON ― The University of Texas MD Anderson Cancer Center and Replay today announced the launch of Syena, a new oncology-focused product company pioneering T cell receptor (TCR ...